<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918589</url>
  </required_header>
  <id_info>
    <org_study_id>13104</org_study_id>
    <nct_id>NCT04918589</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Alloplastic Breast Reconstruction</brief_title>
  <official_title>Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hematoma is a common complication of alloplastic breast reconstruction. This can lead to pain&#xD;
      and discomfort experienced by the patient, in addition to greater use of valuable healthcare&#xD;
      resources. Previous studies have shown correlation between the use of tranexamic acid (TXA),&#xD;
      an anti-fibrinolytic, and reduced post-surgical bleeding complication events.&#xD;
&#xD;
      In this randomized control trial (RCT) assessing TXA use in alloplastic breast&#xD;
      reconstruction, one breast will be randomized to have TXA applied topically, while the other&#xD;
      will have normal saline (NS) placebo applied. The primary objective of this prospective&#xD;
      blinded randomized control trial study is to determine if the administration of topical TXA&#xD;
      in alloplastic breast reconstruction reduces the incidence of surgical site hematoma compared&#xD;
      to placebo within 2 weeks following surgery. The results of this study will be used to inform&#xD;
      the design of a larger multicentered RCT on TXA in breast surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to investigate the use of topical application of&#xD;
      tranexamic Acid (TXA) to the surgical wound as a means to decrease hematoma formation&#xD;
      compared to placebo in patients undergoing alloplastic breast reconstruction. This project is&#xD;
      designed as a single-center RCT to evaluate the effectiveness of topical TXA in this patient&#xD;
      population.&#xD;
&#xD;
      If enrolled in this study, patients individual breasts will be randomly assigned to one of&#xD;
      two treatment groups for to apply to the wound before it is closed.&#xD;
&#xD;
      One breast will have an intravenous form of TXA applied topically to the surgical site. The&#xD;
      other will be have a topical normal saline solution applied to the wound before closure (a&#xD;
      placebo).&#xD;
&#xD;
      The patients will have the standard number of drains and postoperative instructions for&#xD;
      breast reconstruction. They will follow-up at two weeks time in clinic for assessment, and&#xD;
      emergency room visits will be also be evaluated. Standard of care will be practiced with&#xD;
      respect to all procedures and visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial (RCT) with 2 arms: the interventional arm (receiving topical TXA) and the control arm (receiving placebo).&#xD;
Intervention: Topical application of 3 grams of tranexamic acid (30 mL of 100 mg/mL) diluted in 10 mL of normal saline in the breast.&#xD;
Placebo: Topical application of 40 mL of 0.9% normal saline to the breast.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patients will be randomized on the REDCap system. Their assignment will be made available to research team member, which will be preparing syringes with either TXA or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hematoma</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence rate of hematoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroma</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence rate of seroma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drain output</measure>
    <time_frame>24 hours</time_frame>
    <description>Total drain output (mL) at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with drains</measure>
    <time_frame>2 weeks</time_frame>
    <description>Total number of days drains in situ with standard discharge criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of repeat operations required for patient related to complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention rate</measure>
    <time_frame>2 weeks</time_frame>
    <description>Rate of subsequent interventions including aspiration, repeat drain insertion or other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging findings</measure>
    <time_frame>2 weeks</time_frame>
    <description>Ultrasound findings of hematoma or seroma, if applicable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Hematoma Postoperative</condition>
  <condition>Breast Cancer</condition>
  <condition>Tranexamic Acid</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 mL topical of 0.9% normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>40 mL topical of 0.9% normal saline</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are 18 years or older;&#xD;
&#xD;
          -  Are undergoing one- or two-stage bilateral alloplastic breast reconstruction&#xD;
             immediately after bilateral mastectomy at either Hamilton Health Sciences or St.&#xD;
             Joseph's Hospital Hamilton.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking therapeutic anticoagulation;&#xD;
&#xD;
          -  Taking antiplatelet drugs;&#xD;
&#xD;
          -  Pregnant or breast feeding;&#xD;
&#xD;
          -  Allergic to TXA;&#xD;
&#xD;
          -  Cannot provide informed consent;&#xD;
&#xD;
          -  Alloplastic reconstruction is not performed immediately after mastectomy;&#xD;
&#xD;
          -  Have a documented coagulopathy or bleeding disorder, acquired disturbances of colour&#xD;
             vision, subarachnoid hemorrhage, hematuria, irregular menstrual bleeding, or seizure&#xD;
             disorder.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronen Avram, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minh Huynh, MD</last_name>
    <phone>9055221155</phone>
    <email>minh.huynh@medportal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Healthcare, King Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8G 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark McRae, MD, FRCSC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare, Charlton Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophoceles Voineskos, MD, FRCSC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital, Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronen Avram, MD, FRCSC</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012 May 17;344:e3054. doi: 10.1136/bmj.e3054. Review.</citation>
    <PMID>22611164</PMID>
  </reference>
  <reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </reference>
  <reference>
    <citation>De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000 Mar;119(3):575-80.</citation>
    <PMID>10694619</PMID>
  </reference>
  <reference>
    <citation>Ipema HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother. 2012 Jan;46(1):97-107. doi: 10.1345/aph.1Q383. Epub 2011 Dec 27. Review.</citation>
    <PMID>22202494</PMID>
  </reference>
  <reference>
    <citation>Gomez-Barrena E, Ortega-Andreu M, Padilla-Eguiluz NG, Pérez-Chrzanowska H, Figueredo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014 Dec 3;96(23):1937-44. doi: 10.2106/JBJS.N.00060.</citation>
    <PMID>25471907</PMID>
  </reference>
  <reference>
    <citation>Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty. J Arthroplasty. 2013 Aug;28(7):1080-3. doi: 10.1016/j.arth.2012.11.016. Epub 2013 Mar 28.</citation>
    <PMID>23541868</PMID>
  </reference>
  <reference>
    <citation>Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014 Dec;21(6):987-93. doi: 10.1016/j.knee.2014.09.010. Epub 2014 Oct 23. Review.</citation>
    <PMID>25450009</PMID>
  </reference>
  <reference>
    <citation>Knight H, Banks J, Muchmore J, Ives C, Green M. Examining the use of intraoperative tranexamic acid in oncoplastic breast surgery. Breast J. 2019 Sep;25(5):1047-1049. doi: 10.1111/tbj.13409. Epub 2019 Jun 11.</citation>
    <PMID>31187540</PMID>
  </reference>
  <reference>
    <citation>Pinsolle V, Grinfeder C, Mathoulin-Pelissier S, Faucher A. Complications analysis of 266 immediate breast reconstructions. J Plast Reconstr Aesthet Surg. 2006;59(10):1017-24. Epub 2006 Jun 5.</citation>
    <PMID>16996422</PMID>
  </reference>
  <reference>
    <citation>Nelson JA, Fischer JP, Grover R, Cleveland E, Erdmann-Sager J, Serletti JM, Wu LC. The impact of anemia on microsurgical breast reconstruction complications and outcomes. Microsurgery. 2014 May;34(4):261-70. doi: 10.1002/micr.22202. Epub 2013 Nov 4.</citation>
    <PMID>24436188</PMID>
  </reference>
  <reference>
    <citation>Megson M. Traumatic subcutaneous haematoma causing skin necrosis. BMJ Case Rep. 2011 Jul 20;2011. pii: bcr0520114273. doi: 10.1136/bcr.05.2011.4273.</citation>
    <PMID>22689664</PMID>
  </reference>
  <reference>
    <citation>Rogoff H, Marquez JE, Ghosh K, Jou C, McAuliffe P, Rathi S, Monroig K, Medrano C, Marmor WA, Ferrier A, Kapadia K, Klein G, Huston TL, Ganz J, Dagum AB, Khan S, Bui D. Clinical Outcomes After Hematoma Development: A Study of 627 Tissue Expander Breast Reconstructions. Ann Plast Surg. 2020 Jul;85(S1 Suppl 1):S63-S67. doi: 10.1097/SAP.0000000000002343.</citation>
    <PMID>32243320</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alloplastic Breast Reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

